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ABSTRACT We have created a Drosophila model of
lysozyme amyloidosis to investigate the in vivo behavior
of disease-associated variants. To achieve this objec-
tive, wild-type (WT) protein and the amyloidogenic
variants F57I and D67H were expressed in Drosophila
melanogaster using the UAS-gal4 system and both the
ubiquitous and retinal expression drivers Act5C-gal4
and gmr-gal4. The nontransgenic w1118 Drosophila line
was used as a control throughout. We utilized ELISA
experiments to probe lysozyme protein levels, scanning
electron microscopy for eye phenotype classification,
and immunohistochemistry to detect the unfolded pro-
tein response (UPR) activation. We observed that ex-
pressing the destabilized F57I and D67H lysozymes
triggers UPR activation, resulting in degradation of
these variants, whereas the WT lysozyme is secreted
into the fly hemolymph. Indeed, the level of WT was up
to 17 times more abundant than the variant proteins. In
addition, the F57I variant gave rise to a significant
disruption of the eye development, and this correlated
to pronounced UPR activation. These results support
the concept that the onset of familial amyloid disease is
linked to an inability of the UPR to degrade completely
the amyloidogenic lysozymes prior to secretion, result-
ing in secretion of these destabilized variants, thereby
leading to deposition and associated organ damage.—
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Human lysozyme is a 14-kDa globular protein that
plays a role in innate immunity by catalyzing the
hydrolysis of the peptidoglycan components of bacte-
rial cell walls (1). Concordant with this role, the protein
is abundant in secretions such as tears and saliva, but in
the early 1990s, two naturally occurring mutational
variants, the I56T and D67H lysozymes, were found to
result in abnormal deposition of aggregated protein in
organs such as the liver, spleen, and kidney (1, 2). Such
accumulation of protein aggregates is thought to be the
primary cause of dysfunction in these organs and the
resulting syndrome of familial systemic amyloidosis (2,
3). Other lysozyme variants have now been found to be
associated with amyloidosis, including two other single
point mutations (F57I, W64R) and two double muta-
tions (F57I/T70N, T70N/W112R) (4–6).
The folding mechanism of lysozyme has been studied
in great detail (7–18), and it is clear that deposition of
the lysozyme variants is a consequence of the local and
transient unfolding of the protein that results in a high
propensity for the protein to aggregate and form
threadlike structures known as amyloid fibrils. Experi-
mental studies of the misfolding and aggregation be-
havior of lysozyme in vitro have revealed that fibril
formation occurs because the native state of lysozyme is
destabilized in the amyloidogenic variants, resulting in
a decreased difference in the energy barrier between
the native state and partially unfolded intermediates for
these variants relative to the wild-type (WT) protein
(10). As a result, the amyloidogenic variants have a
significantly higher ability, relative to the WT protein,
to populate partially unfolded transient intermediate
species, which leads to the formation of aberrant inter-
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molecular interactions that result in aggregation and
ultimately fibril formation (3, 13, 17, 19–26).
In contrast to the wealth of information about fold-
ing and misfolding processes of the variant lysozymes
in vitro, much less is known about how they fold,
misfold, and aggregate in vivo. Two interesting obser-
vations are that deposits formed in heterozygotic pa-
tients with lysozyme amyloidosis are composed entirely
of the variant proteins (3) and, at least for W64R, that
the circulating levels of the lysozyme variant in patients
appear to be greatly reduced (4). Similarly, low levels of
secretion for the amyloidogenic variant lysozymes have
been observed in studies in which the proteins were
expressed in the yeast Pichia pastoris. In this system, a
direct correlation was found between the secreted
quantity of any given lysozyme variant and the mea-
sured stability of its corresponding native state (27).
Thus, the quality control mechanisms in yeast are able
to recognize destabilized variants of lysozyme and tar-
get them for degradation. Indeed, recent studies have
identified that the expression of the amyloidogenic
lysozyme variant I56T in P. pastoris results in the up-
regulation of genes related to the unfolded protein
response (UPR), endoplasmic reticulum (ER)-associ-
ated degradation (ERAD), and ER-phagy processes,
whereas the WT protein elicits no significant re-
sponse (28).
The presence of misfolded proteins in the ER causes
stress and induces the UPR, whose role is to restore ER
homeostasis. One way in which this situation can be
achieved is by degrading the accumulated misfolded
proteins through ERAD, which is the likely fate of a
substantial population of the destabilized lysozyme vari-
ants. In addition, the UPR also maintains ER homeo-
stasis by decreasing the rate of transcription and trans-
lation, up-regulating the expression of genes that relate
to proteins that assist in correct folding processes,
and expanding the size and capacity of the ER.
However, if homeostasis cannot be achieved and the
UPR is sustained, the result can be the triggering of
cell death (29).
One approach to understanding protein misfolding
diseases in greater detail is to make use of model
organisms such as Drosophila melanogaster, which can
facilitate the investigation of the biological events asso-
ciated with the controlled introduction of peptides or
proteins prone to misfold and to aggregate in vivo. This
method has proved to be of great relevance in studies
of Alzheimer’s disease in which the amyloid -peptide
(A) has been expressed (30–32), for polyglutamine-
repeat disorders, such as Huntington’s disease (33–35),
and for a familial amyloidotic polyneuropathy associ-
ated with mutational variants of transthyretin (36, 37).
To study the in vivo behavior of variant lysozymes, we
have overexpressed the WT protein, the destabilized
non-natural I59T variant, and the amyloidogenic vari-
ants F57I and D67H in different tissues of D. melano-
gaster.
MATERIALS AND METHODS
All restriction enzymes were purchased from New England
Biolabs (Hitchin, UK), PfuTurbo DNA polymerase from
Stratagene Europe (Amsterdam, the Netherlands), and syn-
thetic oligonucleotides from Operon (Cologne, Germany),
and all chemicals were purchased from Sigma-Aldrich
(Gillingham, UK) unless otherwise stated.
Generation of transgenic lysozyme flies
The genes for WT and D67H lysozyme were fused to the 3
end of the coding DNA for an insect secretion signal peptide,
MASKVSILLLLTVHLLAAQTFAQ (38), by PCR amplification
that introduced unique EcoRI and NotI sites at the 5 and 3
ends of the coding sequence, respectively. These sites were
used to clone the constructs into the gal4-responsive pUAST
expression vector to generate UAS-lysozyme transgenes for
pseudorandom incorporation into the genome of D. melano-
gaster. The constructs obtained for WT, F57I, I59T, and D67H
lysozymes were then subcloned using the same sites into the
pBS-LoxP-white-Lox2272 expression vector (a gift from Prof.
Stephen Small, Department of Biology, New York University,
New York, NY, USA), which allows for Cre-mediated recom-
bination for targeted transgenesis in Drosophila (39). The
pBS-LoxP-white-Lox2272 expression vectors containing the
gene encoding WT, F57I, I59T, or D67H were injected by
BestGene Inc. (Chino Hills, CA, USA), using a Drosophila line
that has a chromosome 2 target site.
qRT-PCR analysis
Several lines of pUAST-transgenic flies were created for WT
and D67H lysozyme constructs. Two lines of each (WTa, WTb,
D67Hc, and D67Hd) were selected, and male flies (including
negative control w1118 flies, which do not express human
lysozyme) were crossed with Act5C-gal4 virgins. Twenty male
offspring were collected on the day of eclosion, and RNA was
extracted using the Qiagen RNeasy Mini kit and treated with
RNase-Free DNase (Qiagen Ltd., Crawley, UK) according to
the manufacturer’s protocol for purification of total RNA
from animal tissues. The concentration of total RNA purified
for each line was measured using a NanoDrop 1000 spectro-
photometer (Thermo Fisher Scientific, Loughborough, UK),
and 1 g RNA was then subjected to reverse transcription
using the Promega Reverse Transcription System with oligo
dT primers (Promega, Southampton, UK). qRT-PCR was
performed using a Bio-Rad iCycler and 2X iQ SYBR Green
Supermix (Bio-Rad Laboratories, Hemel Hempstead, UK).
Each sample was analyzed in triplicate with both the target
gene (lysozyme) and the control gene (RP49) primers in
parallel. The primer sequences for the lysozyme gene were
sense, 5-CCAACTACAACGCTGGTGAC-3, and antisense, 5-
CTGCAGCAAAGCAGAACAAG-3; those for the RP49 gene
were sense, 5-ATGACCATCCGCCCAGCATCAGG-3, and
antisense, 5-ATCTCGCCGCAGTAAACG-3. Relative expres-
sion levels were calculated using the Livak method (40).
Immunohistochemistry of larvae
WTb, D67Hc, and control w1118 flies were crossed with
Act5C-gal4 driver flies. Third-instar larvae were dissected in
phosphate-buffered saline (PBS; pH 7.6), and the tracheae
were removed and fixed in 4% w/v paraformaldehyde in PBS
for 30 min at room temperature. Following blocking with
0.5% bovine serum albumin (BSA) and 0.1% Triton X-100,
the tracheae were incubated in a 1:200 dilution of polyclonal
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rabbit anti-lysozyme antiserum (Dako UK Ltd., Cambridge,
UK) overnight at 4°C, followed by 3 washes and then a 1:1000
dilution of alkaline phosphatase (AP) conjugated anti-rabbit
IgG (Promega). We used 5-bromo-4-chloro-3-indonyl-phos-
phatase in conjugation with nitro blue tetrazolium for color-
imetric detection of alkaline phosphatase activity. Samples
were examined at 40 view.
Preparation of lysozyme-specific capture resin
CNBr-activated Sepharose 4B resin (GE Healthcare, Little
Chalfont, UK) was suspended in a 1 mM HCl solution (1:10
resin:solution, w/v) for 15 min with gentle agitation. The
resin was centrifuged (1100 g, 10 min), and the supernatant
was decanted. The resin was then washed 3 times with the HCl
solution, and a 2-ml aliquot of resin suspension was centri-
fuged (2300 g, 2 min), suspended in buffer 1 (0.1 M NaHCO3,
pH 8.3, with 0.5 M NaCl), and centrifuged again (2300 g, 2
min). After washing the resin 3 times in this way, it was
resuspended in 2 ml of 0.5 mg/ml of cAb-HuL6 (the N-ter-
minal domain of a camelid heavy-chain antibody specific of
human lysozyme; ref. 21) dissolved in buffer 1, and incubated
overnight with gentle agitation at 4°C. The resin slurry was
then centrifuged (2300 g, 2 min), and the supernatant was
removed. The resin was successively washed with buffer 1 to
remove excess cAb-HuL6 and then incubated in a 1 M
ethanolamine solution (1 M, pH 8.0, room temperature,
2.5 h), and washed 3 times with buffer 2 (0.1 M acetate, pH 4,
and 0.5 M NaCl) and 3 times with buffer 3 (0.1 M Tris, pH 8,
and 0.5 M NaCl). The cAb-HuL6-conjugated resin was finally
suspended in buffer 3.
Immunoprecipitation
A 100-l aliquot of the cAb-HuL6-conjugated resin slurry was
placed in a Micro Bio-Spin Chromatography Column (Bio-
Rad) and equilibrated by washing the resin 3 times with cold
SuperBlock TBS Blocking Buffer (Pierce, Rockford, IL, USA)
containing EDTA-free protease inhibitors (TBS-PI; Roche
Diagnostics, Burgess Hill, UK). Known numbers of flies
(5–50) were homogenized on ice with a pestle in 1.5-ml
Eppendorf tubes containing cold TBS-PI (200 l). The ma-
terial was then centrifuged (15,700 g, 1 min), and the
supernatant was retained and centrifuged a second time,
again retaining the supernatant. A positive control was pre-
pared by adding an aliquot of purified WT human lysozyme
to the supernatant of the Drosophila w1118 control line (which
does not express human lysozyme). The total protein concen-
tration of the fly supernatant was determined using the DC
Protein Assay (Bio-Rad). The fly supernatant was incubated at
room temperature for 5 min with cAb-HuL6-conjugated resin
equilibrated with TBS-PI. The resin was then centrifuged
(1500 g, 1 min) to remove the supernatant and then washed
3 times with cold TBS-PI. To elute the lysozyme from the
resin, a urea solution (20 l: 9 M urea; 1% w/v SDS; 25 mM
Tris, pH 6.8; and 1 mM EDTA) was added to the resin,
followed by centrifugation (1500 g, 1 min). Samples were
analyzed by Western blotting.
Western blot analysis
Samples were separated on 4–12% NuPAGE gels (Invitrogen,
Paisley, UK). Proteins were transferred to a 0.2-m nitrocel-
lulose membrane (Fisher Scientific, Loughborough, UK) in
Tris-glycine buffer containing 20% v/v methanol and 0.01%
w/v SDS using a Trans-Blot SD semidry electrophoretic
transfer cell (15 V constant, 30 min; Bio-Rad Laboratories).
The blots were probed with rabbit anti-human lysozyme
polyclonal antiserum (Washington Biotechnology, Columbia,
MD, USA) followed by horseradish peroxidise (HRP)-linked
anti-rabbit IgG antiserum (New England Biolabs). The blots
were developed with the Pierce SuperSignal West Pico kit or
Pierce SuperSignal West Femto kit (Perbio Science, Cram-
lington, UK).
Hemolymph isolation
Hemolymph was isolated from offspring of pUAST WT (WTb)
and control w1118 flies crossed with Act5C-gal4 (10 flies) and
gmr-gal4 (30 flies) using the protocol described previously
(36). In brief, a hole was punctured in the base of an
Eppendorf tube with a 22-gauge needle and plugged with
cotton wool. This modified tube was placed in a clean
Eppendorf tube for hemolymph collection. The heads of the
flies were separated from the thorax with a 27-gauge needle,
and both parts were placed in the described apparatus and
centrifuged (2500 g, 5 min). No liquid was observed in the
collection tube at this point, so the fly debris was removed,
and a small volume (5 l) of TBS-PI was added and centri-
fuged (2500 g, 5 min). After this step, the hemolymph sample
was observed in the collection tube; this sample was further
diluted 2- and 5-fold in TBS-PI, and the protein concentration
of the hemolymph was determined using the Bio-Rad DC
Protein Assay. The samples were analyzed by an ELISA
specific for human lysozyme. Levels of lysozyme in the hemo-
lymph were normalized to the total soluble protein concen-
tration in the hemolymph.
ELISA analysis
cAb-HuL6 (5 g/ml in PBS) was adsorbed onto the wells of a
96-well Nunc MaxiSorb microtiter plate (Fisher Scientific) for
1 h at 37°C. The antibody fragment solution was removed,
and the plate was washed 6 times with SuperBlock TBS
Blocking Buffer. The wells were blocked with BSA (10 mg/ml
in TBS) overnight at 4°C. Flies were homogenized in cold
TBS-PI, and the samples were centrifuged (15,700 g, 1 min).
The supernatant was retained and centrifuged a second time,
again retaining the supernatant. A positive control was pre-
pared by adding an aliquot of purified WT lysozyme to the
supernatant of the Drosophila w1118 control line. A standard
curve from known lysozyme concentrations was prepared with
purified human lysozyme (0.8 to 20 g/L) produced recom-
binantly in P. pastoris (27) The total protein concentration in
each Drosophila supernatant solution was determined using
the DC protein assay (Bio-Rad). The supernatant samples,
either undiluted or diluted (1:10 dilution in TBS), were
incubated for 1 h at 37°C in the wells. The wells were then
washed 6 times with TBS and incubated with rabbit anti-
human lysozyme antiserum (diluted 1:1000 in 10 mg/ml BSA
in TBS; Washington Biotechnology) for 1 h at 37°C. The wells
were then again washed 6 times with TBS, followed by
incubation with an alkaline phosphatase-conjugated anti-
rabbit IgG antiserum (diluted 1:2000 in 10 mg/ml BSA in
TBS; New England Biolabs) for 1 h at 37°C. The wells were
then washed with TBS a further 6 times, and detection was
performed with the ELISA amplification kit (Invitrogen),
following the manufacturer’s instructions. The recombinant
cAb-HuL6 capture antibody is specific for human lysozyme
and has a similar affinity (KD 1 nM) for the WT, F57I, and
D67H lysozymes (21). To test for the presence of insoluble
lysozyme in the Drosophila samples, flies were homogenized in
cold TBS-PI and the samples were centrifuged (15700 g, 1
min). As a positive control, an aliquot of preformed lysozyme
fibrils was added to the negative control w1118 sample prior to
homogenization. The supernatant was removed, and the
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insoluble pellet was washed with TBS-PI 3 times, followed by
incubation in DMSO (50 l) for 30 min. The samples were
centrifuged (15,700 g, 1 min), and the supernatant was
removed. The pure DMSO sample was diluted to a final
concentration of 16% DMSO in TBS-PI buffer (to ensure that
the lysozyme present would bind in the ELISA analysis). A
standard curve of known lysozyme concentrations was pre-
pared in the presence of 16% DMSO, and the ELISA analysis
was performed as detailed above.
Scanning electron microscopy (SEM) for Drosophila eye
analysis
pBS WT, F57I, I59T, D67H, and control w1118 flies were
crossed with the driver gmr-gal4. Crosses were performed at
29°C, and the flies were collected on the day of eclosion. Flies
were then dried for 1 d at room temperature, followed by
coating with Au/Pd in a Polaron E5000 (Quorum/Emitech,
Ashford, UK). The external surfaces of the eyes were visual-
ized by SEM, and the architecture of the retina was viewed.
Images were collected using an FEI Philips XL30 scanning
electron microscope at 5 kV (Philips, Amsterdam, The Neth-
erlands).
Preparation of flies and immunohistochemistry for UPR
detection
pBS WT, F57I, I59T, D67H, and control w1118 flies were
crossed with the driver gmr-gal4. Offspring with the genotype
UAS-lysozyme/Cyo;gmr-gal4/TM6B were then crossed with UAS-
xbp1 flies. Flies were maintained at 29°C. Drosophila heads
were embedded on the day of eclosion in Tissue-Tek OCT
compound (Histolab, Go¨teborg, Sweden) using Cryomold-
specimen molds and stored at 80°C until use. The OCT
blocks were sectioned using a Microm HM 550 Cryostat
(Microm International GmbH, Walldorf, Germany) into
14-m thin sections that were placed on SuperFrost Plus
slides (Menzel-Gla¨ser, Braunschweig, Germany) and stored at
20°C until use. The sections were fixed in 4% w/v PFA for
10 min at room temperature. The slides were washed in PBS
(33 min) followed by (13 min) wash in PBS-T (PBS with
0.05% v/v Tween-20) before blocking in 10% w/v BSA in
PBS-T for 1 h at room temperature. Rabbit anti-GFP antibody
(1:2000 in 1% BSA w/v in PBS-T; Chemokine, Secaucus, NJ,
USA) was added to the slides and incubated overnight at 4°C.
The slides were washed with PBS-T (35 min). Goat-anti-
rabbit fluorescently labeled secondary antibody (1:500 in 1%
w/v BSA in PBS-T; Alexa Fluor 594 Goat-anti-Rabbit; Invitro-
gen) was applied to the slides and incubated for 1 h at room
temperature. The slides were washed with PBS-T (310 min),
dipped in dH2O, and allowed to dry for a couple of minutes
in the dark. The slides were mounted using Vectashield with
DAPI (Vector Laboratories, Peterborough, UK) and sealed
with nail polish. The slides were analyzed using a Leica
DM6000 microscope (Leica Microsystems, Wetzlar, Germany)
using the 405/40 nm (for DAPI) and 560/40 nm (for Alexa)
bandpass filters. Micrographs were processed in Adobe Pho-
toshop CS4 (Adobe Systems, San Jose, CA, USA); background
levels were reduced, the signal levels were enhanced, and
scale bars were added. All images were treated identically.
The GFP-positive cells were quantified in a blinded experi-
ment where 16, 15, 14, 21, and 18 micrographs for control,
WT, I59T, D67H, and F57I, respectively, were examined for
GFP-positive cells that colocalized with DAPI.
Statistical analysis
Statistical comparisons were performed with a 2-tailed un-
paired Student’s t test, (GraphPad Prism 5; GraphPad, La
Jolla, CA, USA).
RESULTS
WT lysozyme is efficiently secreted into the fly
hemolymph
In this study, we have investigated the tissue-directed
expression of lysozyme in Drosophila using the UAS-gal4
system (41) and the two drivers Act5C-gal4 (ubiquitous
expression; ref. 42) and gmr-gal4 (retinal expression;
ref. 43). Two different gal4-responsive vectors, pUAST
and pBS-LoxP-white-Lox2272 (pBS), were used to pro-
duce our transgenic models. The important difference
between these transgenesis systems is that pUAST in-
serts pseudorandomly throughout the genome, while
the pBS-LoxP vector directs insertion to a unique
location in an engineered acceptor site (39, 41). In
both cases, the gene for lysozyme was fused to a signal
peptide sequence derived from the Drosophila protein
called necrotic (38), and efficient secretion of the WT
protein was observed for both Act5C-gal4 and gmr-gal4
(Fig. 1). The circulating level of WT lysozyme in the
flies was calculated to be 0.7 mg/L and 0.2 mg/L
when expressed by the Act5C-gal4 and gmr-gal4 drivers,
Figure 1. Secreted levels of lysozyme. ELISA analysis of
hemolymph isolated from offspring of Act5C-gal4 (A) and
gmr-gal4 driver (B) crosses with WTb and w1118 (control) flies.
The analysis clearly shows the presence of human lysozyme in
the WTb line and its absence in the control flies in both cases.
The quantity of lysozyme present in the hemolymph isolates
(solid bars) was found to be65% of the amount of lysozyme
present in the whole fly (shaded bars). Levels of lysozyme in
the hemolymph were normalized to the total soluble protein
concentration in each hemolymph sample. Normalized (ly-
sozyme) values were calculated as nanograms of lysozyme
present per total amount of soluble lysate proteins (mg/ml).
Data are means  sd.
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respectively. Interestingly, these values are in agree-
ment with literature reports of WT lysozyme levels in a
healthy individual being 0.5–3 mg/L (44). In the first
instance, several independent transgenic lines of WT
and D67H lysozymes were generated using the pUAST
plasmid. The transcriptional levels for each line were
analyzed by qRT-PCR to allow selection of WT and
D67H lines that expressed lysozyme at equivalent levels.
Despite large differences in mRNA levels for the vari-
ants, two lines, WTb and D67Hc, yielded equivalent
mRNA levels for WT and D67H lysozyme, respectively
(Fig. 2).
High levels of WT lysozyme are lethal during
metamorphosis
The qRT-PCR analysis confirmed the presence of tran-
scriptionally active lysozyme transgenes for both WT
and D67H-transgenic Drosophila lines. Therefore, we
investigated the effect of expressing WT and D67H
lysozymes ubiquitously in the fly using the driver Act5C-
gal4. When the WTb and D67Hc transgenes were ex-
pressed in this way, we observed partial pupal lethality
(i.e., a substantial number of the flies failed to eclose)
for WT lysozyme (Fig. 3B), but not for the D67H variant
(Fig. 3C). In addition, a more marked lethality was
observed for the WTa line, which thus correlates with
the higher transcriptional activity obtained for WTa
compared to WTb (Fig. 2). In contrast, all flies express-
ing the D67H variant developed normally (Fig. 3C) as
compared to the w1118 control flies (Fig. 3A). Immuno-
histochemistry was used to probe for the presence of
lysozyme; the WT protein was readily detected in the
tracheae of third instar larvae (Fig. 3E), but no staining
was observed for D67Hc or for the control larvae (Fig.
3F, D, respectively).
WT lysozyme is more abundant than the
disease-associated D67H variant
Immunoprecipitation followed by Western blotting of
homogenates from whole flies that expressed lysozyme
ubiquitously demonstrated the presence of both the
WT (Fig. 4A, lanes 4 and 5) and the D67H (Fig. 4A,
lanes 6 and 7) isoforms, with seemingly lower signals for
the D67H variant. To quantify this result, a sensitive
ELISA assay was developed using the recombinant
cAb-HuL6 (the N-terminal domain of a camelid heavy-
chain antibody specific for human lysozyme) as the
capture antibody and a polyclonal antiserum for detec-
tion. From the ELISA results, it was apparent that newly
eclosed flies exhibited 5-fold higher levels for the WT
protein than for the D67H variant (Fig. 4B). These data
confirm the results from the immunohistochemistry
and Western blot experiments, where, in both cases,
higher protein levels were detected for the WT ly-
sozyme than for the D67H variant (Figs. 3E, F and 4A,
lanes 4–7, respectively).
Levels of soluble lysozyme correlate with the
native-state stability of the protein
To determine whether the soluble levels of lysozyme
are related to the native-state stabilities of the proteins,
we used the site-directed insertion method of the pBS
system to generate 4 transgenic lines expressing the WT
Figure 3. Pupae analysis and immunohistochemistry. A–C)
Images of larval development during metamorphosis of Drosoph-
ila expressing no lysozyme (control w1118; A), WT lysozyme
(WTb; B), and D67H lysozyme (D67Hc; C). D–F) Immunohisto-
chemical analysis of trachea tissue, probed with an anti-lysozyme
antibody, of Drosophila expressing no lysozyme (D), WT lysozyme
(E), and D67H lysozyme (F). The lysozyme protein was ex-





Figure 2. qRT-PCR analysis of lysozyme transcription levels.
The levels of lysozyme mRNA in each of two independent
lines of WT lysozyme (WTa and WTb) and of D67H lysozyme
(D67Hc and D67Hd) and w1118 (control) flies were analyzed
by qRT-PCR. The lysozyme protein was expressed using the
Act5C-gal4 driver. All values were normalized against the level
of the housekeeping gene RP49 (see Materials and Methods).
In this analysis, the WT lysozyme line WTb was identified to
have the same mRNA expression level (within 1%) as the
D67H lysozyme line D67Hc, and the controls revealed no
detectable levels of lysozyme (n.d.). Data are means  sd.
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lysozyme; the I59T variant, which has a lower stability
compared to the WT protein; and the most destabilized
amyloidogenic variants, F57I and D67H (3, 17, 18, 45)
at comparable levels. The differences in the native-state
stabilities of WT, F57I, I59T, and D67H lysozymes have
previously been examined, and the midpoints of ther-
mal denaturation are reported to be 79.2  1.4, 60.4 
1.1, 70.1  1.3, and 66.0  2.0°C, respectively (27).
ELISA measurements on flies expressing lysozyme
through the Act5C-gal4 driver revealed that the desta-
bilized F57I and D67H lysozyme variants are present at
substantially lower levels than WT lysozyme and that the
level of soluble protein in Drosophila correlates well with
the stability of the lysozyme variants. The level of the
I59T variant was found to be 3-fold lower than that of
WT but 6-fold higher than that of the amyloidogenic
variants (Fig. 5A). A similar correlation between the
stability of lysozyme and the detected levels of protein
was found in flies expressing lysozyme in the fly retina
through the gmr-gal4 driver, where the detected levels
of the I59T variant were found to be 4-fold lower than
the WT protein but 2- and 3-fold higher than the
amyloidogenic variants F57I and D67H, respectively
(Fig. 5B). The results from the ELISA measurements
are summarized in Supplemental Table S1.
It has been reported that the rates of in vitro aggre-
gation of the amyloidogenic variants, as well as the I59T
variant, are higher than WT lysozyme (17, 23); there-
fore, to determine whether the lower level of soluble
protein was due to the variants being trapped as
insoluble aggregates within the flies, an additional
extraction step using DMSO (which can completely
dissolve fibrils; ref. 46) was added after homogenizing
the flies in TBS-PI. The DMSO extracts were isolated
and analyzed by ELISA. The results showed that a
sample of w1118 control flies that had been spiked with
preformed lysozyme fibrils prior to homogenization
gave a strong positive lysozyme signal in the ELISA
assay; however, no significant signal was detected after
DMSO solubilization of the lysozyme flies crossed with
the gmr-gal4 driver (Supplemental Fig. S1). This sug-
gests that the lower level of soluble protein is due to
degradation of the less stable lysozyme variants and not
due to aggregate accumulation.
Figure 5. ELISA analysis of Drosophila lines expressing ly-
sozyme variants that differ in their native-state stability. ELISA
analysis of offspring, collected at d 0, from various pBS
lysozyme lines. A) Offspring from w1118 (control), WT, I59T,
D67H, and F57I flies that were crossed with the Act5C-gal4
driver, which drives expression of lysozyme ubiquitously.
B) Offspring from control, WT, I59T, D67H, and F57I flies
that were crossed with the gmr-gal4 driver, which drives
expression of lysozyme in the retina of Drosophila eyes. Nor-
malized (lysozyme) values were calculated as nanograms of
lysozyme present per total amount of soluble lysate proteins
(mg/ml). Data are means  sd. Native-state stability of the
lysozyme variants is indicated above each bar; these values are
based on thermal denaturation, as reported previously (27).
Figure 4. Western blot and ELISA analysis of Drosophila lines
expressing lysozyme ubiquitously. A) Western blot analysis of
offspring, collected at d 0, from WT and D67H pUAST
lysozyme lines crossed with the Act5C-gal4 driver (100 flies/
sample), which drives expression of lysozyme ubiquitously.
Lane 1: markers; lane 2: negative control (w1118); lane 3:
positive control (w1118 lysate spiked with recombinant human
lysozyme); lane 4: WTa; lane 5: WTb; lane 6: D67Hc; lane 7:
D67Hd. B) ELISA analysis of offspring, collected at d 0, from
control, WTb, and D67Hc flies that were crossed with the
Act5C-gal4 driver. Normalized (lysozyme) values were calcu-
lated as nanograms of lysozyme present per total amount of
soluble lysate proteins (mg/ml). Data are means  sd.
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Expression of destabilized lysozyme variants in the
retina results in a rough-eye phenotype
Using gmr-gal4 to drive retinal expression of the WT,
F57I, I59T, and D67H lysozymes, a significant rough-
eye phenotype was observed for flies expressing F57I
lysozyme (Fig. 6E). For these flies, the normal regular
pattern of the ommatidia, which is observed in the
gmr-gal4 background w1118 control flies (Fig. 6A), is
highly disrupted, and some of the ommatidia are fused
together. In addition, a mild rough-eye phenotype for
flies expressing D67H lysozyme could be observed
(highlighted by lines in Fig. 6D). This phenotype was
not apparent for the gmr-gal4 background control flies
(Fig. 6A) or when WT or I59T lysozyme was expressed
in the fly retina (Fig. 6B, C, respectively). These results
indicate that the expression of the amyloidogenic ly-
sozyme variants results in significant toxicity during the
development of the Drosophila eye despite the fact that
the major fractions of the proteins are cleared from the
system.
Unfolded protein response is triggered by expression
of the destabilized lysozyme variants
To investigate whether the rough-eye phenotype could
be due to ER stress and the resulting activation of the
UPR, xbp1-EGFP was coexpressed with lysozyme in the
fly retina using gmr-gal4. The marker xbp1-EGFP can be
used specifically to detect the Ire-1 pathway of the UPR
activation. Splicing of a transgenic xbp1-EGFP-mRNA
by Ire-1 brings the EGFP coding sequence into frame,
generating a signal that can be detected by a variety of
microscopic techniques (47).
The Ire-1-dependent generation of EGFP in horizon-
tal micrographs of the eye of an adult fly was detected
using an antibody against GFP followed by a fluorescent
secondary antibody. Because of the nuclear localization
sequence within xbp1, xbp1-EFGP accumulates in the
nuclei and is observed as red dots in the micrographs
(Fig. 7A–E, arrows). Accumulation of GFP in the cell
nuclei (red stain) was confirmed by colocalization with
the nuclei-specific stain DAPI (blue stain; Fig. 7F).
When expressing xbp1-EGFP in the gmr-gal4 back-
ground of control w1118 flies, a low signal can be
observed, which reveals a basal level of UPR activation
in the fly retina (Fig. 7G). No notable increase in the
activation of UPR was observed for WT or I59T when
expressed through the gmr-gal4 driver (Fig. 7G). In
contrast, expression of F57I and D67H resulted in a
significant increase in the activation of the UPR, as
indicated by the higher number of GFP-positive cells
appearing in the micrographs (Fig. 7G). Interestingly,
these data show that the UPR is activated by the most
destabilized amyloidogenic variants, which also display
a distinct rough-eye phenotype (Fig. 6D, E).
DISCUSSION
Individual human patients expressing one of the natu-
rally occurring amyloidogenic lysozyme variants (I56T,
F57I, W64R, D67H, F57I/T70N, and T70N/W112R)
are at risk of amyloid deposition in a range of tissues,
including the spleen and kidney (48). The consequent
syndrome, termed systemic amyloidosis, is thought to
result primarily from the presence of large quantities of
insoluble protein aggregates, causing disruptive effects
on the organs involved (2, 3). Interestingly, neither the
spleen nor the kidney synthesizes significant quantities
of lysozyme (49), and therefore the variant proteins
must be transported to these sites via circulation in the
blood. Although there is clinical evidence that patients
expressing lysozyme variants have reduced levels of this
Figure 6. SEM analysis of rough-eye phenotype. Images of Drosophila eyes obtained by SEM for gmr-gal4 background control w1118
(A), WT (B), I59T (C), D67H (D), and F57I (E). A significant disruption in the eye structure was found for the F57I line. The
somewhat smaller disruption in the regular pattern of the ommatidia for the D67H line is highlighted by red lines. The lysozyme
protein was expressed using the gmr-gal4 driver. Scale bars  50 m.
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protein in circulation, comprehensive data are not
available (4); it appears, however, that despite the
patients being heterozygous, only the variant protein
has been identified in the amyloid deposits (2).
An important goal of this study was to compare the
potentially toxic consequences of the expression of WT
and amyloidogenic lysozymes in Drosophila. In this
respect, the F57I and D67H variants were chosen for
our study since the mutations are found naturally,
causing hereditary non-neuropathic systemic amyloido-
sis (2, 5, 49), and the native state of these lysozyme
variants is very significantly destabilized relative to the
WT protein (18). To explore the relationship between
the secreted levels of lysozyme in Drosophila and the
stability of various lysozyme variants, the non-natural
I59T variant was also included in our study since its
stability is intermediate between that of the WT protein
and the stabilities of the F57I and D67H variants (45).
Gene expression and protein secretion
To ensure that comparisons of the results for the WT
and mutational variants are meaningful, we identified
transgenes that transcribed the different forms of
lysozyme with equal efficiency. This objective was
achieved in two ways. First, we generated flies that are
transgenic for both the WT and D67H constructs by
random genomic insertion and then screened by qRT-
PCR for lysozyme mRNA to find pairs of lines that
express lysozyme at equal levels. Second, we used
site-directed transgenesis to create flies carrying each of
the constructs (WT, F57I, I59T, and D67H) at the same
genomic location, thus eliminating any effects of differ-
ent positions of insertion. In this way, we have been able
to perform the study using well-matched fly lines ex-
pressing the WT and the variant lysozymes.
Analysis of the results from ELISA experiments re-
veals that in all tissues, the levels of soluble lysozyme for
the WT flies are much higher, 5–17 times more abun-
dant, than the protein levels obtained for the F57I and
D67H variants. The soluble lysozyme in the I59T flies is
at an intermediate level, 3–4 times lower as compared
to WT flies but 3–6 times higher with respect to F57I
and D67H flies. Thus, there is a clear correlation
between the degree of native-state destabilization of
each variant and the reduction in the amount of
secreted protein. This finding is consistent with previ-
ous studies of lysozyme expression in yeast (27) and
strongly suggests that the quality control systems of
both yeast and Drosophila are able to detect and to clear
destabilized lysozyme variants.
Lysozyme toxicity during metamorphosis
Interestingly, we found that high levels of ubiquitously
expressed WT lysozyme are lethal during metamorpho-
sis, as revealed by the failure of a substantial amount of
the pupae expressing the protein to reach maturity and
eclose. Lysozyme catalyzes the hydrolysis of glycosidic
bonds between N-acetylmuramic acid and N-acetyl-d-
glucosamine residues in peptidoglycans, but it is also
capable of degrading chitin, a polysaccharide found in
the outer skeleton of insects (50); therefore, although
the mechanism of toxicity has not been established, it is
likely to be related to the enzymatic activity of the
highly abundant WT lysozyme during metamorphosis.
Deleterious effects of lysozyme in the adult fly retina
We have found that expression of the variant F57I
lysozyme in the fly retina of the developing eye results
in a pronounced disruption of the eye structure. A mild
rough-eye phenotype was also detected for retinal ex-
pression of D67H but not for the more stable WT or
I59T proteins. This observation is remarkable, given
Figure 7. Immunohistological anal-
ysis of UPR activation. Histological
sections of heads of Drosophila ex-
pressing lysozyme using the gmr-gal4
driver were stained with anti-GFP
antibody to detect spliced xbp1-
EGFP as a marker for IRE1-positive cells, indicating UPR activation (arrows). Red stain shows GFP signal enhanced by Alexa
594-nm secondary antibody. Blue shows staining of cell nuclei by DAPI. A–F) gmr-gal4 background control w1118 (A), WT (B),
I59T (C), D67H (D), and F57I (E); accumulation of GFP in the cell nuclei was confirmed by colocalization with DAPI (F).
Micrographs were taken at 40. Scale bars  50 m. G) Scatter plot shows number of GFP-positive cells for each variant of
lysozyme. Micrographs were examined for GFP-positive cells in a blind experiment. Asterisks indicate significant increase of
GFP-positive cells compared to control. **P 	 0.01, ***P 	 0.001.
8 Vol. 26 January 2012 KUMITA ET AL.The FASEB Journal  www.fasebj.org
the low level of protein secretion in the adult fly retina,
for the F57I and D67H variants relative to WT lysozyme.
In contrast to the findings of A aggregates in a
Drosophila model of Alzheimer’s disease that were pro-
posed to cause the observed rough-eye phenotype (30),
no accumulation of the lysozyme variants has been
detected in our fly model (Supplemental Fig. S1).
Consequently, we sought to investigate whether the eye
phenotype of F57I and D67H could be a result of stress
caused by the presence of misfolded lysozyme in
the ER.
Role of the UPR system
UPR is a downstream response to stress in the ER
allowing the cell to cope with the overload of unfolded/
misfolded proteins (29). By using the xbp1-EGFP re-
porter to probe the activation of the UPR we were able
to demonstrate that the UPR is indeed activated in the
neuronal tissue of the fly retina when expressing the
disease-associated lysozyme variants F57I and D67H.
Moreover, the UPR activation correlates with the eye
phenotype as large amounts of EGFP were detected for
F57I and D67H, which also show disruption in the eye
structure during the development of the Drosophila eye.
In contrast, expressing WT or I59T in the fly retina
does not activate the UPR and does not cause a
rough-eye phenotype.
As discussed above, the detectable levels of F57I and
D67H are much lower than that of the WT protein
despite equal transcriptional levels between F57I,
D67H, and WT, confirmed by qRT-PCR (Supplemental
Fig. S2). The low stability and, consequently, the high
amyloidogenic properties of F57I and D67H compared
to WT lysozyme (18) make the F57I and D67H variants
less likely to fold correctly in the neurons, resulting in
an increase in the quantity of misfolded proteins in the
ER. This will cause ER stress and activation of the UPR,
which in turn leads to the degradation of the protein by
up-regulation of genes that promote ERAD of these
unstable variants. In contrast, the highly stable WT
protein does not activate the UPR and is therefore not
degraded; consequently, a high level of protein is
observed in the ELISA measurement. Interestingly, our
findings are in close agreement with a recent study,
which monitored the up-regulation of genes involved in
UPR, ERAD, and ER-phagy in P. pastoris expressing
different lysozyme variants (28); in both cases, a strong
correlation was observed between the decrease in ly-
sozyme native stability and an increase in UPR activa-
tion.
Linking UPR activation with disrupted retinal
development
Activation of the UPR correlates with the presence of a
rough-eye phenotype, since UPR activation is notice-
ably higher for the F57I and D67H lysozyme variants,
which both show a significant eye phenotype compared
to WT and I59T, where no such phenotype is apparent.
An important function of the UPR is to maintain
protein homeostasis and thus to protect the cells from
being overloaded by unfolded or misfolded proteins
that eventually would lead to cellular dysfunction and
to apoptosis (51, 52). However, if the ER stress is high
and prolonged, the UPR will be unable to counteract
the accumulation of various unfolded or misfolded
proteins, and consequently other pathways may activate
the apoptotic process (53).
Activation of Ire-1 up-regulates ERAD and promotes
degradation of various ER-localized mRNA molecules.
This effect reduces the protein load on the stressed ER
and allows reprogramming of ER-associated protein
synthesis (29). Notably, in our Drosophila system, Ire-1
will constantly be activated by the production of the
least stable misfolded lysozyme variants and therefore
prevent recovery of protein synthesis in the developing
eye. This effect by itself may cause the panel of proteins
necessary for correct eye development to be out of
balance, resulting in failure of the compound eye to
develop normally. Alternatively, or in addition, pro-
longed activation of Ire-1 in the fly retina during eye
development may activate pathways that, in turn, in-
duce cell death (29).
CONCLUSIONS
The delicate balance between the propensity for a
misfolded protein to be cleared or to aggregate is a
crucial feature that can dictate whether amyloid disease
occurs or is avoided. Although the native-state stabilities
of the amyloidogenic variants of lysozyme are decreased
in thermal stability by13–19°C with respect to the WT
protein, they are still relatively stable proteins with
values of Tm 
 60°C (27). Nevertheless, our data show
that the amyloidogenic variants are sufficiently destabi-
lized to trigger the UPR, resulting in the clearance of a
large proportion of the protein; therefore, it would
appear that the quality control mechanisms within a
healthy organism are quite stringent. In light of our
findings, we speculate that the onset of familial amyloid
disease may be linked to the inability of the UPR to
detect and target for degradation the entire population
of the amyloidogenic variants prior to secretion, allow-
ing a proportion of these destabilized species to enter
circulation and eventually to aggregate and accumulate
in the body as intractable deposits. Thus, enhancing,
directly or indirectly, the quality control system for
patients with protein misfolding diseases could be
beneficial to allow degradation of the misfolded vari-
ants, thereby preventing their secretion and eventual
aggregation in different organs with fatal outcome.
The fact that the WT and I59T lysozymes exhibit
significantly higher levels of secretion compared to
F57I and D67H in our Drosophila model system will
provide an opportunity to screen for potential pharma-
cological and genetic modifiers of the ER quality con-
trol system, using the protein levels of WT and I59T as
readouts. The discovery of agents or gene products that
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enhance the quality control system, for example, by
lowering the secreted level of WT and I59T lysozymes,
will constitute potential targets for therapeutic im-
provement of the quality control system. Also, pharma-
cological agents and gene products that inhibit aspects
of the proteostasis machinery can be screened by the
search for products that increase the secreted levels of
F57I and D67H.
The Drosophila model system presented in this work
reveals some of the consequences of UPR activation
when lysozyme is overexpressed in the fly. This unique
model also provides an initial foundation for generat-
ing further insights into the mechanism by which
amyloidogenic lysozyme variants are able to evade the
quality control system to an extent that the protein can
aggregate in patients with these genetic mutations.
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